OncoMatch/Clinical Trials/NCT04623931
Chemotherapy and Radiation Therapy for the Treatment of IDH Wildtype Gliomas or Non-histological (Molecular) Glioblastomas
Is NCT04623931 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Temozolomide for anaplastic astrocytoma, idh-wildtype.
Treatment: Temozolomide — This phase II trial studies how well temozolomide and radiation therapy work in treating patients with IDH wildtype historically lower grade gliomas or non-histological molecular glioblastomas. Radiation therapy uses high-energy x-rays to kill tumor cells and shrink tumors. Giving chemotherapy with radiation therapy may kill more tumor cells. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. The goal of this clinical research study is to compare receiving new radiation therapy doses and volumes to the prior standard treatment for patients with historically grade II or grade III IDH wild-type gliomas, which may now be referred to as IDH wildtype molecular glioblastomas at some institutions. Receiving temozolomide in combination with radiation therapy may also help to control the disease.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Chemotherapy
Cancer type
Glioblastoma
Biomarker criteria
Required: IDH1 wild-type
Required: IDH2 wild-type
Disease stage
Required: Stage II, III (WHO)
Excluded: Stage I, IV
Historical grade II and III gliomas
Prior therapy
Cannot have received: cranial radiotherapy
Prior cranial radiotherapy or radiotherapy to the head and neck where potential field overlaps would exist
Cannot have received: chemotherapy for any brain tumor
Prior chemotherapy or radiotherapy for any brain tumor
Lab requirements
Blood counts
Absolute neutrophil count (ANC) ≥ 1,500 cells/mm^3; Platelets ≥ 100,000 cells/mm^3; Hemoglobin ≥ 10.0 g/dl (transfusion/intervention allowed)
Kidney function
Blood urea nitrogen (BUN) < 30 mg/dl; Serum creatinine < 1.5 mg/dl
Liver function
Bilirubin ≤ 1.5 upper limit of normal (ULN); ALT and AST ≤ 3 x ULN
ANC ≥ 1,500 cells/mm^3; Platelets ≥ 100,000 cells/mm^3; Hemoglobin ≥ 10.0 g/dl; Bilirubin ≤ 1.5 ULN; ALT and AST ≤ 3 x ULN; BUN < 30 mg/dl; Serum creatinine < 1.5 mg/dl
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- M D Anderson Cancer Center · Houston, Texas
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT04623931 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Does this trial require IDH1?
Yes, IDH1 wild-type is a required biomarker for enrollment.
Does this trial require IDH2?
Yes, IDH2 wild-type is a required biomarker for enrollment.
What disease stage is eligible?
Stage II or III is required.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages